SCHEMBL1012535

SCHEMBL1012535

C=CCOC(CC)OP(=O)(O)O

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.42
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LAP3 P28838 1/20 0.33
LPAR2 Q9HBW0 1/20 0.31
LPAR3 Q9UBY5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324049 0.79 SMPD1 (0.46) SMPD1LAP3
SCHEMBL2048208 0.78 SMPD1 (0.48) SMPD1MEN1KMT2ALAP3LPAR2
SCHEMBL28192080 0.77 LPAR3 (0.42) SMPD1LPAR2LPAR3
SCHEMBL27823317 0.77 SMPD1 (0.56) SMPD1LAP3LPAR2LPAR3
SCHEMBL5303308 0.77 MEN1 (0.40) MEN1KMT2A
SCHEMBL1012660 0.77 SMPD1 (0.32) SMPD1LPAR2LPAR3
SCHEMBL4896522 0.76 SMPD1 (0.34) SMPD1LPAR2LPAR3
SCHEMBL2048023 0.75 SMPD1 (0.50) SMPD1LAP3LPAR2LPAR3
Phosphoric Acid SCHEMBL1012536 0.73 TSHR (0.36) MEN1KMT2ALAP3
SCHEMBL18048851 0.73 SMPD1 (0.30) SMPD1LPAR2LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2842559-A2 Compounds, compositions and methods for the treatment of viral infections and other medical disorders Chimerix, Inc. (US) 2015-03-04 EP disclosed
US-20110015149-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS CHIMERIX, INC. 2011-01-20 US disclosed
US-7517858-B1 Prodrugs of pharmaceuticals with improved bioavailability THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-14 US disclosed
EP-1865967-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS Chimerix, Inc. (US) 2007-12-19 EP disclosed
WO-2006110656-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS CHIMERIX INC (US) 2007-03-01 WO disclosed
US-20070003608-A1 Compounds, compositions and methods for the treatment of viral infections and other medical disorders CHIMERIX, INC. 2007-01-04 US disclosed
WO-2006110656-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS CHIMERIX, INC. (US) 2006-10-19 WO disclosed
EP-0837630-A4 PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY UNIV CALIFORNIA (US) 1998-11-25 EP disclosed
EP-0837630-A1 PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-04-29 EP disclosed
WO-1996039831-A1 PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015149-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS ACE, CYP27A1, LIPC SMPD1 57/4885MEN1 3708/4885KMT2A 1424/4885
US-20070003608-A1 Compounds, compositions and methods for the treatment of viral infections and other medical disorders ACE, CYP27A1, LIPC SMPD1 57/4885MEN1 3708/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.